Search results for "Amyotrophic Lateral Sclerosis"

showing 10 items of 228 documents

Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival.

2010

Abstract Background Percutaneous endoscopic gastrostomy (PEG) is offered to amyotrophic lateral sclerosis (ALS) patients with severe dysphagia. Immediate benefits of PEG are adequate food intake and weight stabilization. However, the impact of PEG on survival is still uncertain. In this work we retrospectively evaluated the effect of PEG on survival in a cohort of ALS patients followed in a tertiary referral centre. Methods Between 2000 and 2007, 150 dysphagic ALS patients were followed until death or tracheostomy. PEG was placed in 76 patients who accepted the procedure and survival was analysed using the Kaplan–Meier life-table method. Results In ALS patients submitted to PEG, no major co…

MaleVital capacitymedicine.medical_specialtyPalliative caremedicine.medical_treatmentmacromolecular substancesEndoscopy GastrointestinalCohort StudiesPercutaneous endoscopic gastrostomyPEG ratiomedicineHumansAmyotrophic lateral sclerosisAgedRetrospective StudiesGastrostomybusiness.industryAmyotrophic Lateral Sclerosistechnology industry and agricultureRetrospective cohort studyMiddle Agedmedicine.diseaseDysphagiaSurgerySurvival RateTreatment OutcomeNeurologyFemaleNeurology (clinical)medicine.symptombusinessDeglutition DisordersCohort studyFollow-Up StudiesJournal of the neurological sciences
researchProduct

BRAIN-TARGETED SOLID LIPID NANOPARTICLES CONTAINING RILUZOLE: PREPARATION, CHARACTERIZATION AND BIODISTRIBUTION

2009

Aim: Developments within nanomedicine have revealed a great potential for drug delivery to the brain. In this study nanoparticulate systems as drug carriers for riluzole, with sufficiently high loading capacity and small particle size, were prepared to a reach therapeutic drug level in the brain. Materials & method: Solid lipid nanoparticles containing riluzole have great potential as drug-delivery systems for amyotrophic lateral sclerosis and were produced by using the warm oil-in-water microemulsion technique. The resulting systems obtained were approximately 88 nm in size and negatively charged. Drug-release profiles demonstrated that a drug release was dependent on medium pH. Biodi…

Maleamyotrophic lateral sclerosisBiodistributionMaterials scienceSOLID LIPID NANOPARTICLES BRAIN TARGETING RILUZOLEBiomedical EngineeringDrug delivery to the brainMedicine (miscellaneous)NanoparticleBioengineeringDevelopmentPharmacologyRats Sprague-DawleyPlasmaDrug StabilitySolid lipid nanoparticlemedicineAnimalsHumansGeneral Materials ScienceParticle Sizebiodistributionmodified releaseDrug CarriersRiluzoleBrainLipidsRiluzoleRatssolid lipid nanoparticlesNeuroprotective AgentsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanomedicineNanoparticlesParticle sizeDrug carriermedicine.drug
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

2014

Importance There is an urgent need to identify reliable biomarkers of amyotrophic lateral sclerosis (ALS) progression for clinical practice and pharmacological trials. Objectives To correlate several hematological markers evaluated at diagnosis with ALS outcome in a population-based series of patients (discovery cohort) and replicate the findings in an independent validation cohort from an ALS tertiary center. Design, Setting, and Participants The discovery cohort included 712 patients with ALS from the Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis from January 1, 2007, to December 31, 2011. The validation cohort comprised 122 patients with ALS at different stages of…

MaleanalysisGastroenterologyCohort Studieschemistry.chemical_compoundAdult Aged Aged; 80 and over Amyotrophic Lateral Sclerosis; blood/mortality/pathology Biological Markers; blood Cohort Studies Creatinine; blood Disease Progression Female Humans Italy Lymphocyte Count Male Middle Aged Outcome Assessment (Health Care) Predictive Value of Tests Prognosis Sensitivity and Specificity Serum Albumin; analysisblood/mortality/pathologyOutcome Assessment Health Care80 and overAged 80 and overeducation.field_of_studybiologymedicine.diagnostic_testHazard ratioMiddle AgedPrognosisItalyErythrocyte sedimentation rateCreatinineCohortDisease ProgressionSettore MED/26 - NeurologiaBiological MarkersFemaleCohort studyAdultmedicine.medical_specialtyPopulationSerum albuminSensitivity and SpecificityOutcome Assessment (Health Care)bloodPredictive Value of TestsInternal medicinemedicineHumansLymphocyte CounteducationSerum AlbuminAgedCreatininebusiness.industryAmyotrophic Lateral SclerosisAlbuminchemistryImmunologybiology.proteinNeurology (clinical)ALSbusinessBiomarkersJAMA neurology
researchProduct

TELEPHONE FOLLOW-UP FOR PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS

2007

The relentless evolution of amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disorder of the upper and lower motoneurons, leads to an increasing level of disability. Most patients, during the course of the disease, become unable to attend the tertiary clinical care center and are thus prevented from enrolling in clinical trials or benefiting from specialized care and management. The main objective of this study was to verify whether the ALS functional rating scale (ALSFRS) could be reliably administered by telephone to patients, when unable to attend the ALS clinic, or to their caregivers. ALSFRS is a validated instrument that assesses the functional status and the disease pr…

Malemedicine.medical_specialtyAdaptive equipmenttelephone interviewDiseaseSeverity of Illness IndexInterviews as Topicdisease progressionSwallowingRating scaleActivities of Daily LivingSeverity of illnessmedicineHumansamyotrophic lateral sclerosiAmyotrophic lateral sclerosisAgedbusiness.industryMiddle Agedamyotrophic lateral sclerosis functional rating scalemedicine.diseaseClinical trialCaregiversNeurologyTelephone interviewPhysical therapyFemaleAMYOTROPHIC LATERAL SCLEROSISNeurology (clinical)businessFollow-Up Studies
researchProduct

The serum level of free testosterone is reduced in amyotrophic lateral sclerosis

2002

Sporadic amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting upper and lower motoneurons. There is an approximately 2:1 higher incidence of ALS in men compared to women, and this has raised the hypothesis of an involvement of sex hormones in the etiopathogenesis of the disorder. In this work, the serum levels of dehydroepiandrosterone sulphate (DHEAS), 17-betaestradiol, free and total testosterone were measured in 35 patients with defined or probable ALS, according to the El-Escorial/WFN revisited criteria, and compared to those obtained from 57 disease controls, matched for age and gender to the ALS group. We found no differences between ALS cases and …

Malemedicine.medical_specialtyCentral nervous system diseaseDehydroepiandrosterone sulphateDegenerative diseaseSex hormone-binding globulinInternal medicinemedicineHumans17-βestradiol; Amyotrophic lateral sclerosis; Dehydroepiandrosterone sulphate; Motoneurons; Sex hormone binding globulin; TestosteroneTestosteroneAmyotrophic lateral sclerosisAged17-βestradiolAged 80 and overSex Characteristicsbiologybusiness.industryTestosterone (patch)Middle Agedmedicine.diseaseAmyotrophic lateral sclerosisPathophysiologySex hormone binding globulinMotoneuronsEndocrinologyNeurologybiology.proteinFemaleNeurology (clinical)businessSex characteristicsHormone
researchProduct

A case-control study of amyotrophic lateral sclerosis

1991

A retrospective case-control study was conducted using 46 patients affected by amyotrophic lateral sclerosis and 92 closely matched healthy controls. Cases were ascertained through typical clinical and instrumental findings. Putative risk factors (bone fractures or major trauma, exposure to domestic animals, surgical operations, disease among first degree relatives and others) were investigated anamnestically using a standard questionnaire. Using Mantel-Haenzsel estimates of the odds ratio, no association was found between amyotrophic lateral sclerosis and the investigated variables.

Malemedicine.medical_specialtyEpidemiologybusiness.industryAmyotrophic Lateral SclerosisCase-control studyRetrospective cohort studyDiseaseOdds ratiomedicine.diseasePhysical medicine and rehabilitationItalyRisk FactorsCase-Control StudiesInternal medicinemedicineHumansFemaleSettore MED/26 - NeurologiaNeurology (clinical)First-degree relativesAmyotrophic lateral sclerosisbusinessRetrospective Studies
researchProduct

MTHFR C677T allelic variant is not associated to plasma and cerebrospinal fluid homocysteine in amyotrophic lateral sclerosis

2014

Amiotrophic lateral sclerosis (ALS) is a neurological disorder with a multifactorial etiopathogenesis including excitotoxicity, intracellular calcium increase and mitochondrial damage together with oxidative stress and apoptosis. Overall, the relationship between homocysteine (Hcy), motoneuron death and ALS appears to be complex and still under investigation. It has been already shown that Hcy is elevated in plasma and cerebrospinal fluid (CSF) of ALS patients, although mechanisms of hyperhomocysteinemia have not been elucidated yet. MTHFR C677T variant is the most common genetic determinant of increased homocysteinemia, but no studies regarding the effect of this polymorphism in ALS patien…

Malemedicine.medical_specialtyHomocysteineGenotypeClinical Biochemistrychemistry.chemical_compoundCerebrospinal fluidInternal medicineGenotypeMedicineMthfr c677tHumansamyotrophic lateral sclerosiAlleleAmyotrophic lateral sclerosismethylenetetrahydrofolate reductase (MTHFR)AllelesMethylenetetrahydrofolate Reductase (NADPH2)Cerebrospinal Fluidbiologybusiness.industryBiochemistry (medical)Amyotrophic Lateral SclerosisGenetic VariationGeneral MedicinehomocysteineMiddle Agedmedicine.diseaseEndocrinologychemistryMethylenetetrahydrofolate reductaseMTHFRbiology.proteinFemalebusiness
researchProduct

Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis

2020

Recent publications showed that circulating neurofilaments (Nfs) may be used as a diagnostic biomarker distinguishing amyotrophic lateral sclerosis (ALS) from ALS mimics with high sensitivity and specificity.1–3 Furthermore, it has been shown that patients with higher Nf levels show faster disease progression1 and shorter survival.2 3 Nf levels remain rather stable during the course of disease.2 Current literature suggests that the diagnostic value of neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains in cerebrospinal fluid is about equal, whereas in blood NfL seems to be superior.4 In this study, we investigated the effect of a high-caloric fatty diet (HCFD) on …

Malemedicine.medical_specialtyNeurofilament[SDV]Life Sciences [q-bio]blood [Neurofilament Proteins]PlaceboDiet High-FatGastroenterology03 medical and health sciencesblood [Amyotrophic Lateral Sclerosis]0302 clinical medicineNeurofilament ProteinsInternal medicinePost-hoc analysismedicineHumansddc:610Amyotrophic lateral sclerosisMESH: Neurofilament ProteinsComputingMilieux_MISCELLANEOUSMESH: Amyotrophic Lateral SclerosisRandomized Controlled Trials as TopicMESH: HumansMESH: Middle Agedbusiness.industryTherapeutic effectAmyotrophic Lateral SclerosisMiddle Agedmedicine.diseaseMESH: Male3. Good healthRiluzole[SDV] Life Sciences [q-bio]Psychiatry and Mental healthMESH: Diet High-FatMESH: Randomized Controlled Trials as TopicTolerabilitystatistics & numerical data [Randomized Controlled Trials as Topic]motor neuron diseasePopulation studySurgeryFemaleNeurology (clinical)businessMESH: Female030217 neurology & neurosurgerymedicine.drug
researchProduct

Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder

2017

Introduction: Lower urinary tract symptoms (LUTS) are frequent in motor neuron disease (MND) patients, but clinical factors related to them are unknown. We describe differences in LUTS among MND phenotypes and their relationship with other clinical characteristics, including prognosis. Methods: For this study, we collected clinical data of a previously published cohort of patients diagnosed with classical amyotrophic lateral sclerosis (cALS), progressive muscular atrophy (PMA) or primary lateral sclerosis (PLS) with and without LUTS. Familial history was recorded and the C9ORF72 expansion was analysed in the entire cohort Patients were followed-up for survival until August 2016. Results: Fi…

Malemedicine.medical_specialtyNeurogenic bladder030232 urology & nephrologyDiseaseMuscular Atrophy Spinal03 medical and health sciencesSex Factors0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsC9orf72Primary lateral sclerosisInternal medicinemedicineHumansLower urinary tract symptomsMotor neuron diseaseMotor Neuron DiseaseUrinary Bladder NeurogenicFamily historyAmyotrophic lateral sclerosisAgedPrimary Lateral SclerosisC9orf72 Proteinbusiness.industryAmyotrophic Lateral SclerosisMiddle AgedProgressive muscular atrophyPrognosismedicine.diseaseAmyotrophic lateral sclerosisSurvival AnalysisSurgeryUrodynamicsCross-Sectional StudiesPhenotypeNeurologyProgressive muscular atrophyAmyotrophic lateral sclerosis Lower urinary tract symptoms Motor neuron disease Neurogenic bladder Primary lateral sclerosis Progressive muscular atrophy UrodynamicsMultivariate AnalysisCohortFemaleNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct